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The new H2S-releasing compound ACS94 exerts protective effects through the
modulation of thiol homoeostasis
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aDepartment of Life Sciences, University of Siena, Siena, Italy; bDepartment of Pharmaceutical Sciences, Universita degli Studi di Milano,
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ABSTRACT
The synthesis of a new dithiolethione-cysteine ethyl ester hybrid, ACS94, its metabolites, and its effect on
GSH levels in rat tissues and on the concentration of circulating H2S is described. ACS94 rapidly enters the
cells, where it is metabolised to cysteine and the dithiolethione moiety ACS48. Experiments performed
through the oral administration of ACS94 to healthy rats showed that it is capable of increasing the GSH
levels in most of the analysed organs and the concentration of circulating H2S. Although the increase in
GSH concentration was similar to that obtained by ACS48 and N-acetylcysteine ethyl ester, the H2S
increase was long-lasting and more evident with respect to the parent molecules. Moreover, a decrease of
homocysteine in several rat organs and in plasma was noted. This effect may represent a potential thera-
peutic use of ACS94, as hyperhomocysteinaemia is considered a risk factor for cardiovascular diseases.
Lastly, ACS94 was more efficient than N-acetylcysteine in protecting the liver and kidneys against acute
acetaminophen toxicity.
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Introduction
The physiological function of hydrogen sulphide (H2S) has recently
been discovered, and a potential therapeutic use of this gas for
the treatment of all diseases characterised by inflammation, oxida-
tive stress, and glutathione (GSH) depletion has been suggested1,2.
One possible approach for the therapeutic administration of H2S
is represented by molecules capable of releasing it in a slow and
controlled manner, thus mimicking that which takes place on a
physiological level.
We have experimented on two different classes of H2S-donat-
ing compounds: dithiolethiones and cysteine (Cys) prodrugs.
Dithiolethiones are a class of sulphur-containing molecule,
primarily of synthetic origin, but also found in trace amounts in
certain cruciferous vegetables. They have been established as
anticarcinogens and protective compounds against radiation injury
and hepatotoxicity induced by carbon tetrachloride or acetamino-
phen (APAP)3. Dithiolethiones have been found to behave as H2S
donors under physiological conditions4. Several hybrids were
obtained by grafting 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione
(ADTOH) into existing drugs5,6. The in vitro tests for these com-
pounds suggest that, in addition to maintaining the parent mole-
cule’s therapeutic capacities, they also have several other
advantages (e.g. protection of gastric mucosa [ACS14, ACS15],
much greater histone deacetylase inhibition than valproic acid
[ACS2], blockage of superoxide formation, and downregulation of
NADPH oxidase [ACS6]) (Figure 1)7. The common mechanisms
through which the addition of the ADTOH moiety exerts these
pharmacological effects seem to be based on the concomitant
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increase of both GSH and H2S, although several aspects still need
to be clarified.
GSH plays an important role in the detoxification of xenobiot-
ics, of their metabolites, and of reactive oxygen species (ROS), and
would, therefore, be attractive for increasing its availability in
man. As Cys concentration in cells is limiting to GSH synthesis,
supplementing Cys or its precursors appears to be a logical choice
for boosting its levels in cells. Cys is generally not used because it
is rapidly oxidised to the insoluble cystine form, thus making the
preparation of stable formulations difficult. Furthermore, it has
been reported that Cys at high concentrations is toxic for cultured
cells, and its content is therefore usually kept low in parenteral
formulations8. This has stimulated the use of pharmacologically
useful Cys prodrugs. The simplest derivative of cysteine is N-ace-
tylcysteine (NAC), and numerous studies have already been
reported in which NAC has been administered by either an oral or
intravenous route9,10. In addition to the established pharmaco-
logical actions of NAC (mucolytic agent and antidote for acet-
aminophen intoxication), there are a plethora of others with the
common effect of protecting against oxidative stress, a condition
caused by an imbalance between pro-oxidant production and
antioxidant defence, which is thought to be related to several
pathological conditions, such as age-related diseases, atheroscler-
osis, diabetes, and cancer11. However, large clinical trials have
failed to confirm this supposed protective effect of NAC12, thus
stimulating the research of alternative molecules. We have
recently studied N-acetylcysteine ethyl ester (NACET) as a new
GSH enhancer. NACET is a derivative of NAC, and it is obtained
through the esterification of its carboxylic group with ethanol.
This modification renders the molecule more lipophilic, thus
improving its pharmacokinetic behavior13. NACET resulted to be
significantly more effective than NAC in increasing the circulating
levels of both H2S and GSH content in several rat organs.
On these grounds, we have synthesised ACS94, a new dithiole-
thione-cysteine ethyl ester hybrid. ACS94 has been obtained by
binding 4–(3-thioxo-3H-1,2-dithiol-4-yl)benzoic acid (ACS48) to the
amino group of cysteine ethyl ester (Scheme 1), with the assump-
tion that the two parts of the new chemical entity could have a
synergic effect in increasing H2S levels, as well as in correcting the
redox imbalance process present in several diseases, through an
increase in tissue GSH. Here, the effect of ACS94 on the thiol pool
and on H2S generation is evaluated in comparison to ACS48 and
NAC/NACET. The protective effects against acetaminophen over-
dose are also investigated. Furthermore, the identification and the
synthesis of the main metabolites of ACS94 are described.
Experimental
Materials and methods
General
Unless otherwise indicated, all the chemicals and solvents required
for the syntheses and the analyses were of high purity grade and
were purchased from Sigma-Aldrich (S.R.L., Milano, Italy). CC¼ flash
column chromatography. Melting points (m.p.) were determined in
open capillary tubes with a B€uchi apparatus (Buchi Italia s.r.l.,
Cornaredo, Italy) and were uncorrected. 1H-NMR and 13C-NMR spec-
tra were recorded with a Varian 300MHz Oxford spectrometer
(Varian, Palo Alto, CA) equipped with a non-reverse probe at 25 C,
using DMSO-d6 as a solvent. The chemical shifts were expressed in
ppm (d), coupling constants (J) in Hertz (Hz). The high-resolution
mass spectra (HRMS) were performed with an Apex II ICR-FTMS
Bruker Daltonics mass spectrometer (Bruker Italia, Srl, Milano, Italy)
in positive or negative electrospray ionization (ESI).
The N-acetylcysteine ethyl ester (NACET)14 and 4–(3-thioxo-3H-
1,2-dithiol-4-yl)benzoic acid (ACS48)15 were synthesised according
to the procedures used in the literature.
Figure 1. Chemical structure of several representative hybrids derived by conjugating ADTOH with existing drugs. ACS14: ADTOH grafted into aspirin; ACS15: ADTOH
grafted into diclofenac; ACS2: ADTOH grafted into valproic acid; ACS6: ADTOH grafted into sildenafil.
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3-Mercapto-2-(4-(3-thioxo-3H-1,2-dithiol-4-yl)benzamido)propanoic
acid ethyl ester (ACS94)
A solution of (S)-trityl-L-cysteine ethyl ester16 (625mg; 1.60mmol)
and trietylamine (TEA; 0.2ml) in anhydrous N,N-dimethylforma-
mide (DMF; 7ml) was added to a solution of 4-(3-thioxo-3H-1,2-
dithiol-4-yl)benzoic acid (ACS48; 407mg; 1.60mmol), 1-hydroxy-
benzotriazole (HOBt; 294mg; 1.92mmol), and 1-ethyl-3-(3-dime-
thylaminopropyl)carbodiimide hydrochloride (EDAC; 368mg;
1.92mmol) in anhydrous DMF (3ml). The mixture was stirred for
4 h at r.t. under N2. Following the evaporation of the solvent
under reduced pressure, the residue was taken up with CH2Cl2
and the organic phase was washed with water, dried over anhyd-
rous Na2SO4, and evaporated to dryness. The crude compound
was then purified by CC (silica gel; CH2Cl2 as eluent), yielding
pure 2-(4-(3-thioxo-3H-1,2-dithiol-4-yl)benzamido)-3-(tritylthio)pro-
panoic acid ethyl ester (659mg; yield 66%). M.p. 86–93 C. 1H-
NMR (DMSO-d6): d¼ 9.22 (s,1H); 8.96 (d, J¼ 7.91Hz, 1H); 7.90 (d,
J¼ 8.50Hz, 2H); 7.68 (d, J¼ 8.50Hz, 2H); 7.35–7.22 (m, 15H);
4.25–4.17 (m, 1H); 4.02–3.95 (q, J¼ 6.45Hz, 2H); 3.31 (s, 1H);
2.83–2.71 (q, J¼ 12.90Hz, 1H); 1.09–1.04 (t, J¼ 7.04Hz, 3H).
The trityl deprotection of the thiol was performed by dissolving
2-(4-(3-thioxo-3H-1,2-dithiol-4-yl)benzamido)-3-(tritylthio)propanoic
acid ethyl ester (240mg; 0.38mmol) in 4N HCl in dioxane (10ml)
at 0 C; water (1ml) was added, and the mixture was stirred at
0 C for 30min. The solvent was evaporated to dryness, and the
residue was taken up with ether and then evaporated. This pro-
cedure was repeated several times to ensure the complete elimin-
ation of HCl and dioxane. After rinsing the residue, first with
CH2Cl2 and then with ether, pure ACS94 (117mg; yield 80%) was
obtained. M.p. 109–111 C. 1H-NMR (DMSO-d6): d¼ 9.22 (s, 1H);
8.84 (d, J¼ 7.63Hz, 1H); 7.93 (d, J¼ 8.21Hz, 2H); 7.68 (d,
J¼ 8.21Hz, 2H) 4.56–4.50 (m,1H); 4.11 (q, J¼ 7.03Hz, 2H);
2.99–2.83 (m,1H); 2.68 (t, J¼ 7.92Hz, 1H); 1.18 (t, J¼ 7.03Hz, 3H).
13C-NMR (75MHz, DMSO- d6): d¼ 214.0, 170.8, 166.7, 160.4, 137.0,
133.0, 127.8, 129.3, 61.1, 56.1, 25.5, 14.5. HRMS (ESI) m/z calcd for
C15H15NO3S4Na [MþNa]þ: 407.98270; found: 407.98251.
Diethyl 3,30-disulfanediylbis(2-(4-(3-thioxo-3H-1,2-dithiol-4-yl)ben-
zamido)propanoate) ACS96
A solution of L-cystine ethyl ester dihydrochloride17 (300mg;
0.81mmol) and N,N-diisopropylethylamine (DIPEA; 0.68ml;
3.9mmol) in anhydrous DMF (3ml) was added drop wise to a
solution of ACS48 (413mg; 1.9mmol), HOBt (338mg; 2.28mmol),
and EDAC (436mg; 2.28mmol) in anhydrous DMF (4ml). The mix-
ture was stirred at r.t. for 24 h, under N2. After the solvent was
evaporated to dryness, the crude residue was taken up with
CH2Cl2 and the organic solution was washed with water, dried
over anhydrous Na2SO4, and evaporated to dryness. The crude
compound was then purified by CC (silica; CH2Cl2/MeOH; 99:1).
After rinsing with ether, pure ACS96 was obtained (222mg; yield
36%). M.p. 98–102 C.
1H-NMR: (DMSO-d6) d¼ 9.18 (s, 2H); 8.97 (d, J¼ 7.43Hz, 2H);
7.87 (d, J¼ 8.26Hz, 4H); 7.65 (d, J¼ 7.98Hz, 4H); 4.77–4.70 (m, 2H);
4.16–4.09 (q, J¼ 7.15Hz, 4H); 3.31–3.09 (m, 4H); 1.20–1.16 (t,
J¼ 7.17Hz, 6H). 13C-NMR (75MHz, DMSO-d6): d¼ 214.0, 171.0,
166.6, 160.4, 147.5, 137.0, 133.8, 129.3, 127.7, 61.5, 52.5, 14.5.
HRMS (ESI) m/z calcd for C30H28N2O6S8Na [MþNa]þ: 790.96052;
found: 790.96138.
3,30-Disulfanediylbis(2-(4-(3-thioxo-3H-1,2-dithiol-4-yl)benzamido)-
propanoic acid) ACS97
A solution of cystine tertbutyl ester18 (700mg; 1.95mmol) and trie-
tylamine (TEA; 0.659ml; 4.68mmol) in anhydrous DMF (4ml) was
added to a solution of ACS48 (1g; 3.9mmol), HOBt (716.5mg;
4.68mmol) and EDAC (896mg; 4.68mmol) in anhydrous DMF
(4ml) and the mixture was stirred at r.t. for 24 h, under N2. After
the solvent was evaporated to dryness, the crude residue was
taken up with CH2Cl2, and the organic solution was washed with
water, dried over anhydrous Na2SO4, and evaporated to dryness.
The crude compound was then purified by CC (silica gel; CH2Cl2/
MeOH; 99:1). After rinsing with ether, pure tertbutyl 3,30-disulfane-
diylbis(2-(4-(3-thioxo-3H-1,2-dithiol-4-yl)benzamido)propanoate)
Scheme 1. Reagents and conditions: (a) HOBt, EDAC, TEA, anh. DMF, 4h, r.t.; (b) 4N HCl in dioxane-H2O (90:10), 30min, 0 C; (c) HOBt, EDAC, DIPEA, anh. DMF, 24h,
r.t.; (d) HOBt, EDAC, TEA, anh. DMF, 24h, r.t.; (e) 4N HCl in dioxane-H2O (86:14), 3h, r.t.
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was obtained (910mg; yield 57%). M.p. 88–90 C. 1H-NMR
(DMSO-d6): d¼ 9.18 (s, 2H); 8.97 (d, J¼ 7.43 Hz, 2H); 7.87 (d,
J¼ 8.26 Hz, 4H); 7.65 (d, J¼ 7.98, 4H); 4.77–4.70 (m, 2H);
3.31–3.09 (m, 4H); 1.48 (s, 18H).
Water (5ml) was added to a solution of tertbutyl 3,30-disulfane-
diylbis(2-(4-(3-thioxo-3H-1,2-dithiol-4-yl)benzamido)propanoate)
(910mg; 1.1mmol) in 4N HCl in dioxane (30ml) at 0 C as a scav-
enger, and the mixture was stirred at r.t. for 3 h. The solvent was
evaporated to dryness and the residue was taken up with ether
and then evaporated. This procedure was repeated several times
to ensure the complete elimination of HCl and dioxane. After rins-
ing the residue, first with CH2Cl2 and then with ether, pure ACS97
(686mg; yield 87%) was obtained. M.p. 254–255 C. 1H-NMR
(DMSO-d6): d¼ 9.19 (s, 2H); 8.85 (d, J¼ 7.98Hz, 2H); 7.87 (d,
J¼ 8.25Hz, 4H); 7.64 (d, J¼ 8.25Hz, 4H); 4.73–4.67 (m, 2H);
3.55–3.07 (m, 4H). 13C-NMR (75MHz, DMSO-d6): d¼ 214.0, 172.4,
166.5, 160.2, 147.5, 136.9, 134.0, 129.2, 127.6, 52.5. HRMS (ESI) m/z
calcd for C26H19N2O6S8 [M–H]
–: 710.90143; found: 710.90386.
Animals
Sprague–Dawley male rats (300 g) were purchased from Charles
River (Calco, Milan, Italy). The rats were kept under controlled con-
ditions (22–24 C, relative humidity 40–50%, under a 12-h light/
dark cycle) and fed ad libitum for 2–3weeks before their use and
during the experiments. All animal handling procedures were car-
ried out in accordance with the European Community guidelines
for the use of laboratory animals. The experiments were author-
ised by the local ethical committee of the University of Siena.
Identification of the main metabolites of ACS94
The rats were implanted with either a single or double valve
(model 415, 18 18mm and model 620, 20 20mm; Danuso
Instruments, Milan, Italy). The jugular and femoral veins were can-
nulated (Dow Corning Silastic 0.51mm id, 0.94mm od) for com-
pound administration (femoral) and blood collection (jugular), as
previously described19. The valve was implanted under pentobar-
bital anaesthesia (50mg/kg) 2 days prior to the experiment, and
the animals were allowed to move about freely before and during
the experiments.
The rats received intravenous (iv) administrations of ACS94
(20mg/kg) through the femoral vein. At the indicated times,
blood aliquots (200 ll each) were collected through the valve con-
nected to the jugular vein in tubes containing 5 ll 50mg/ml
K3EDTA, and were immediately centrifuged at 10,000g for 20 s
to obtain plasma.
The analysis of the ACS94 metabolites in the plasma was car-
ried out by deproteinising one aliquot of plasma (50 ll) through
the addition of three volumes of acetonitrile. The supernatants
were then acidified through the addition of trifluoroacetic acid
and were loaded into HPLC. The HPLC separation was performed
on a C18 column (Zorbax Eclipse XDB-C18 4.6mm 150mm,
5 lm; Agilent Technologies, Milan, Italy). Elution conditions:
solvent A¼ sodium acetate 0.25% (v/v) pH 3.09; solvent
B¼ acetonitrile; 0–5min: 94% solvent A/6% solvent B; 5–10min
linear gradient from 6% to 10% solvent B, 10–10.5min linear gra-
dient from 10% to 14% solvent B, 10.5–14.5min 14% solvent B,
14.5–15min linear gradient from 14% to 25% solvent B, 15–19min
linear gradient from 25% to 33% solvent B. A constant flow rate
Figure 2. Scheme of the metabolic pathway of ACS94 leading to thiols (Cys and ACS98), symmetrical disulphides (ACS96, ACS97), asymmetrical disulphides (ACS94-Cys
and ACS99).
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of 1.2ml/min was applied. Detection was performed at 390 nm
excitation and at 480 nm wavelength emission. Asymmetrical
disulphide with Cys (ACS94-Cys) was produced by reacting 0.2M
ACS94 with 0.1M cystine in a 10mM phosphate buffer pH 8.0 for
2 days at room temperature. The identities of the peaks were ana-
lysed by adding the standard compounds, by analysing the same
samples pretreated with dithiotreithol (DTT), and by comparing
the retention times of the different peaks. One aliquot of plasma
(20ll) was used for H2S analysis.
For the study of drug distribution, animals were treated with
endovenous infusion through the femoral vein with a solution of
20mg/kg ACS94 or vehicle. After 60min of the treatment rats
were killed by decapitation, blood (about 2ml) was collected in
EDTA-containing tubes (50ll of 50mg/mL K3EDTA in saline) and
organs were rapidly removed, washed in NaCl 0.9% (w/v) and
then immediately frozen in liquid nitrogen and stored at –80 C
until analyses. Aliquots of blood (0.4ml) were rapidly centrifuged
at 10,000g for 20 s to obtain plasma. Plasma was stored at
–20 C and used for the analysis of metabolites and total thiols.
Erythrocytes were washed in Naþ/Kþ phosphate buffered saline
containing 5mM glucose and then haemolysed by the addition of
100 volumes of 0.02M Naþ/Kþ phosphate buffer. One aliquot of
frozen tissues was homogenised (1:10, w/v) by Teflon/glass potter
in acetonitrile for the analysis of ACS94 and its metabolites (see
procedure described above); one other aliquot was homogenised
(1:5, w/v) in a 20% (w/v) TCA solution containing 1mM K3EDTA
and 0.2mM diethylenetriaminepentaacetic acid (DTPA) for H2S
detection. A third aliquot of frozen tissues was used for
thiol analysis.
Evaluation of GSH replenishing effect and modulation of
Hcys levels
Animals implanted with a single valve for blood collection were
treated orally (by gavage) with 10mg/kg twice a day of ACS94 or
equimolar NAC, NACET, ACS48 for four days. Aliquots of blood
(0.2ml) were collected every 12 h for H2S analysis. On the morning
of the day after the last treatment (i.e. about 12 h from the last
treatment), the rats’ blood and organs were rapidly removed
under anaesthesia (pentobarbital, 50mg/kg). Plasma was obtained
through the centrifugation of whole blood at 10,000g for 20 s.
One aliquot (20ll) was used for the fresh analysis of H2S, whereas
the rest of the plasma was stored at –80 C for the analysis of the
total thiols. The organs were washed in NaCl 0.9% (w/v) and then
immediately frozen in liquid nitrogen and stored at –80 until the
time of analyses. The GSH was measured in the organ homoge-
nates through HPLC after conjugation with monobromobimane
(mBrB), as previously described20. After pretreatment with DTT
and labelling with mBrB (see above), the total thiols (i.e. the sum
of both the reduced and the disulphide form concentration) in
the plasma was measured through HPLC.
Production of hydrogen sulphide
H2S was detected through a modification of the methylene blue
method21 coupled with HPLC detection, as previously described22. In
short, 20ll of fresh plasma was added to 40ll of a 20% (w/v) TCA
solution containing 1mM K3EDTA and 0.2mM DTPA. After 30 s of
centrifugation at 10,000g, 40ll of the supernatant were added
with 5ll of N,N-dimethyl-p-phenylenediamine sulphate (DPD, 20mM
in 7.2N HCl), followed by 5ll of FeCl3 (30mM in HCl 1.2N); after 200
of incubation in the dark, the samples were separated through
HPLC using a Zorbax Eclipse XDB-C18 column (4.6 150mm, 5lm;
Agilent Technologies). The methylene blue formed from the reaction
of H2S with DPD in the presence of FeCl3 was monitored at a wave-
length of 667nm using a diode array detector.
Protection against acetaminophen overdose
The animals were randomly divided into four groups, each consist-
ing of four animals. APAP was dissolved in saline and injected ip
at the dose of 2 g/kg. The group 1 rats served as a control group,
and received a single dose ip injection of 1ml saline containing
10% DMSO and 0.5% carboxymethylcellulose. The group 2 rats
were treated with a single dose of APAPþ vehicle. The group 3
and 4 rats received APAPþACS94 (50mg/kg) or equimolar NAC.
The research drugs, dissolved in saline containing 10% DMSO and
0.5% carboxymethylcellulose, were administered orally 15min
before and 2 and 4h after APAP administration. Six hours after
the APAP treatment, the rats were anaesthetised with pentobar-
bital (60mg/kg), after which blood from the abdominal aorta and
organs were collected for biochemical analyses. After conjugation
with mBrB, as above described, the GSH and Hcys were measured
in the tissue homogenates through HPLC. After the pretreatment
of the samples with DTT, the total Hcys was measured in the
plasma through HPLC and mBrB labelling. The alanine aminotrans-
ferase, aspartate aminotransferase, lactate dehydrogenase, uric
acid, urea, and creatinine in the plasma were measured using the
Roche COBAS 6000 instrument (Roche Diagnostics S.p.A. Monza
(MB), Italy). The protein SH groups (PSH) were determined in ali-
quots of TCA deproteinised samples: specifically, the protein pel-
lets were re-suspended with a glass rod in a 0.2M phosphate
buffer, pH 7.4, containing 2% (w/v) sodium dodecyl sulphate, and
were put in a shaker until complete dissolution. Aliquots of the
samples were then diluted with the same buffer and reacted with
an excess of DTNB, as previously described23.
An Agilent series 1100 HPLC (Agilent Tecnologies Italia,
Cernusco sul Naviglio (MI), Italy). equipped with diode array and
a fluorimetric detector was used for all determinations. All the
spectrophotometric determinations were carried out using a Jasco
V/550 instrument (Jasco Europe, Cremella (LC), Italy).
Statistics
The data are expressed as means ± SD. The differences between
the means were evaluated using one-way analysis of variance
(ANOVA) with the Newman–Keuls multiple test, as appropriate. A
value of p< .05 was considered statistically significant.
Results
Chemistry
3-Mercapto-2-(4-(3-thioxo-3H-1,2-dithiol-4-yl)benzamido)propanoic
acid ethyl ester (ACS94) and its two main metabolites diethyl 3,30-
disulfanediylbis(2-(4-(3-thioxo-3H-1,2-dithiol-4-yl)benzamido)propa-
noate), ACS96 and 3,30-disulfanediylbis(2-(4–(3-thioxo-3H-1,2-
dithiol-4-yl)benzamido)propanoic acid) ACS97 have been synthes-
ised, respectively, by coupling 4-(3-thioxo-3H-1,2-dithiol-4-yl)ben-
zoic acid (ACS48)15 with (S)-trityl-L-cysteine ethyl ester16, followed
by deprotection of the thiol group with HCl in dioxane, or with
cystine ethyl ester dihydrochloride17, or with cystine tertbutyl
ester18 followed by deprotection of the carboxylic moieties with
HCl in dioxane (Scheme 1). In all cases the reactions were per-
formed at room temperature, in anhydrous DMF, using EDAC,
HOBt, and TEA or DIPEA as coupling reagents.
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Biological results
ACS94 metabolism
The metabolism of ACS94 was firstly studied after its intravenous
administration to rats. The metabolites investigated are reported
in Figure 2. Specifically, ACS94 is supposed to undergo three dif-
ferent reactions: a) oxidation of the –SH group through thiol-disul-
phide exchange reactions; b) de-esterification by physiological
esterases; c) hydrolysis of the amide bond between the parent
compounds. As a result of these reactions, a lot of different
metabolites may form. Firstly, it can produce both the parent mol-
ecules cysteine ethyl ester (CysEE) and then Cys and ACS48 (reac-
tion 1), or it can be de-esterified to ACS98 (reaction 2). In
addition, the –SH group can oxidise to form several symmetrical
or asymmetrical disulphides: the symmetrical disulphides can form
between either two ACS94 molecules (ACS96, reaction 3) or two
de-esterified ACS94 molecules (ACS97, reaction 7); the asymmet-
rical disulphides may involve ACS94 with either Cys (reaction 4) or
with ACS98 (to form ACS99, reaction 8), but, also, with all thiols
and disulphides present in rat plasma. In addition, ACS99 can be
obtained through the partial de-esterification of ACS96 (reaction
5), and can be hydrolysed to ACS97 (reaction 6). In Figure 3(A),
the levels of ACS94 are reported in comparison with those of total
ACS94. From this point onward, the term totACS94 is used to refer
to all the metabolites of ACS94 that can be reversibly converted
into this compound through the thiol-disulphide exchange reac-
tion: ACS94 itself, the symmetric disulphide (i.e. ACS96), the
ACS94-moiety in the asymmetrical disulphide (ACS99), and the
ACS94-moiety in the asymmetrical disulphide with Cys. ACS94 dis-
appeared rapidly from the plasma and was, in part, oxidised to
ACS96 and ACS99. In fact, plasma is an oxidising compartment
rich in disulphides24 that can oxidise ACS94 through several differ-
ent thiol-disulphide exchange reactions (i.e. with the reactive –SH
group of albumin and with low molecular mass thiols/disulphides).
The concentration of the de-esterified metabolites (both in the
reduced and oxidised form) and of the dithiolethione moiety
(ACS48) is reported in Figure 3(B). All the compounds, with the
exception of ACS48, exhibited near bi-exponential decay. The rea-
son for these slight discrepancies with classical bi-exponential
decay most likely lies in the thiol-disulphide exchange reactions
that may occur and the great number of physiological thiols
involved. Figure 3(A,B) suggests both a rapid metabolism and/or
high distribution volume of ACS94, even if the latter is difficult to
calculate accurately. It should be noted that ACS48 appeared
immediately after iv infusion, and was still present at relevant con-
centrations after 4 h (Figure 3(B)).
NACET was shown to rapidly cross cell membranes and to then
be de-esterified and trapped inside the cells13. To verify whether
this mechanism also characterises ACS94 metabolism, a further
experiment consisting in the iv administration of ACS94 and the
analysis of the distribution of its metabolites in several rat tissues
after 60min from the treatment was carried out (Table 1). The
data indicate that after 60min from the treatment the major
metabolites occurring in most of the analysed tissues (RBC
included) are represented by the de-esterified forms of ACS94.
The most abundant metabolite occurring intracellularly was always
ACS98, the de-esterified form of ACS94, with a minor content of
ACS48 and ACS94. The treatment also induced a significant
increase in H2S in most of the studied tissues.
Figure 3. ACS94 metabolism. Plasma levels of ACS94 and its metabolites after
the iv administration of 20mg/kg to rats. Times of analysis are: 20, 100 , 300, 60,
1200 , 2400 . Data are the mean± SD; n¼ 3. (A) tot ACS94¼ ACS94þ 2x
ACS96þACS99þ 1/2 ACS94-Cys; (B) tot de-esterified forms: ACS98þ
2xACS97þ 1/2 ACS99.
Table 1. Endovenous treatment with ACS94 and ACS48.
Treatment ACS94 totACS94
tot
de-esterified ACS48 H2S
Plasma
ACS94 2.53 ± 0.33 16.8 ± 2.5 2.96 ± 0.26 16.2 ± 0.6 0.355 ± 0.025

Vehicle – – – – 0.251 ± 0.055
RBCs
ACS94 0.984 ± 0.062 1.24 ± 0.023 14.6 ± 0.5 10.2 ± 0.3 ND
Vehicle – – – – ND
Liver
ACS94 2.23 ± 0.41 2.02 ± 0.54 20.1 ± 1.2 10.7 ± 0.9 0.407 ± 0.005

Vehicle – – – – 0.222 ± 0.048
Kidney
ACS94 0.847 ± 0.06 1.05 ± 0.08 18.4 ± 1.5 9.84 ± 0.7 0.369 ± 0.015

Vehicle – – – – 0.185 ± 0.049
Lung
ACS94 0.555 ± 0.031 0.784 ± 0.03 13.2 ± 1.8 7.25 ± 0.40 0.310 ± 0.061

Vehicle – – – – 0.195 ± 0.010
Heart
ACS94 0.355 ± 0.027 0.535 ± 0.089 8.45 ± 0.61 3.22 ± 0.028 0.286 ± 0.022
Vehicle – – – – 0.251 ± 0.113
Brain
ACS94 0.236 ± 0.033 0.296 ± 0.060 8.56 ± 0.63 3.75 ± 0.13 0.449 ± 0.036

Vehicle – – – – 0.294 ± 0.015
Metabolites of ACS94 in several rat tissues after a 60-min infusion with 20mg/kg
ACS94. Data are expressed as lM and are the mean ± SD of n¼ 4 treatments.
p> .05,

p< .01 vs vehicle.
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Effect on GSH and homocysteine levels
To evaluate the ability of ACS94 to modulate the thiol to disulphide
balance in blood and in solid tissues the drug was orally adminis-
tered for 4 days in comparison with NAC, NACET, and ACS48. Our
previous data indicate that by these selected conditions of treat-
ment both NACET and some dithiolethione molecules are able to
affect the levels of thiols13,25. The rats treated with ACS94 exhibited
higher tissue GSH concentrations, particularly in the liver and kid-
neys. Significant increases in GSH vs both vehicle- and NAC-treated
rats were also found in the lungs, heart, and brain. In addition, the
treatment with ACS94 induced a significant rise of total GSH (i.e.
the sum of the reduced and the oxidised forms of GSH) in plasma
(Figure 4(A)). Conversely, the treatments were unable to influence
tissue GSH levels in the other analysed tissues, namely the testis,
spleen, and muscle (data not shown). This effect on GSH levels was
similar to that induced by NACET and ACS48 (Figure 4(A)). ACS94
also increased GSH levels in some rat organs and in plasma after iv
administration (20mg/kg, Figure 5(A)). This effect was observed in
the liver, kidneys, and brain.
Interestingly, the increase in GSH was in most cases associated
to a decrease in Hcys. In the experiment where the drugs were
orally administered for 4 days, ACS94 and ACS48 lead to a signifi-
cant decrease of homocysteine in the plasma, kidneys, and liver.
In the NACET-treated animals, a decrease of Hcys levels in the kid-
neys and liver was also observed, but not in the plasma
(Figure 4(B)). This decrease was also found in the plasma, liver,
and kidneys after single iv treatments with 20mg/kg ACS94
(Figure 5(B)).
In addition to these data on thiol replenishment, we also
studied the activity of some antioxidant enzymes in rat organs
(namely glutathione reductase, glutathione peroxidase, superoxide
dismutase) but we did not find any significant alteration induced
by ACS94 (data not shown).
Hydrogen sulphide production
H2S production from cells, in vivo, can be stimulated primarily by
increasing cellular stores of cysteine, which can function as a
Figure 4. Concentration of GSH and Hcys in several rat organs and tissues after oral treatment. The rats were orally administered 10mg/kg ACS94, equimolar ACS48,
NAC, NACET or vehicle twice a day for 4 days. Glutathione (A) and homocysteine (B) were measured in organ homogenates through HPLC. The total GSH and total
Hcys were measured in the plasma. Data are the mean± SD; n¼ 3. p< .001 vs vehicle; p< .05 vs vehicle.
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substrate of cystathionine c-lyase (CSE). We, therefore, compared
the circulating levels of H2S after the iv or oral administration of
ACS94 with those obtained after treatment with equimolar doses
of NAC, NACET, or ACS48 (Figure 6(A,B)). As for the other analo-
gous dithiolethione containing molecules, ACS94 increased the
H2S levels in the rat plasma. The levels of H2S in the plasma from
the iv treated rats peaked immediately after NACET infusion,
whereas ACS94 evoked a significant but slower and more stable
increase of H2S concentration (Figure 6(A)). ACS48 induced an
increase of H2S levels with a pattern similar to ACS94. The H2S
measured after the oral treatments indicated ACS94 as the best
molecule for increasing its plasma levels (Figure 6(B)). No increase
of H2S levels was observed in the rats treated with NAC.
Protection against acetaminophen toxicity
Acetaminophen metabolism is known to involve cytochrome P450
to form N-acetyl-p-benzoquinone imine (NAPQI), which causes
hepatic damage. It has been suggested that NAPQI reacts with
free thiol groups of proteins and, in turn, leads to mitochondrial
damage and nuclear DNA fragmentation26. As NAPQI detoxifica-
tion proceeds through GSH conjugation, GSH becomes depleted
in APAP overdose. In addition to its ability to increase GSH pro-
duction, as ACS94 bears an –SH group, it may also play a direct
protective role against APAP damage. This potential protective
effect in rats was studied in acute poisoning experiments, and in
comparison with NAC, which is the drug clinically used to treat
this kind of intoxication.
Following the ip administration of 2 g/kg of APAP to the rats, a
decrease of GSH and protein thiols was particularly evident in the
liver but was also found in the kidneys and heart. The oral admin-
istration of ACS94 was more effective than NAC at preventing this
decrease (Figure 7(A,B)) in all the studied organs (liver, kidneys,
heart). The levels of Hcys were not influenced by the treatment
with APAP but they decreased when the combined treatments
APAPþACS94 were carried out (Figure 7(C)). This effect was
observed not only in the studied organs (liver, kidneys, lung), but
also in the plasma, where the tHcys levels decreased significantly
Figure 5. Concentration of GSH and Hcys in several rat organs and tissues after intravenous treatment. The rats were iv administered 20mg/kg ACS94. After 60min
glutathione (A) and homocysteine (B) were measured in organ homogenates through HPLC. The total GSH and the total Hcys were measured in the plasma. Data are
the mean± SD; n¼ 3. p< .001 vs vehicle.
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from 6.22 ± 0.3 to 4.01 ± 0.07 lM, p< .01). This decrease was not
able to be observed in the NAC-treated animals. In addition, most
of the indicators of liver/kidney damage were consistently lower
in the ACS94 treated animals with respect to those treated with
NAC (Table 2).
Discussion
This manuscript describes the basic features of several biochem-
ical/pharmacological effects of the new chemical entity ACS94.
ACS94 was synthesised with the aim of obtaining a new drug
effective at increasing the levels of GSH and H2S, with the
assumption that this could have beneficial effects on human
health, mainly in the presence of pathologies characterised by
redox imbalance, such as Parkinson disease27, Alzheimer’s dis-
ease28,29, osteoarthritis30, psoriasis, and skin diseases31.
GSH plays a protective role in relation to cellular oxidative
damage, which mostly occurs during inflammation. If the oxidative
stress is severe, glutathione disulphide (GSSG) may accumulate,
leading to protein S-glutathionylation, with the activation/inactiva-
tion of several regulatory pathways32. A GSH decrease can also
occur through irreversible conjugation with electrophilic species
and the formation of chemically stable sulphides of GSH, which
Figure 6. Concentration of H2S in plasma of rats treated with ACS94. The rats were either iv (A) or orally (B) administered with NAC, NACET, ACS94, ACS48, vehicle.
For iv treatment, a dose of 20mg/kg of ACS94 (or equimolar NACET and ACS48) was used. For oral treatment, 10mg/kg of ACS94 (or equimolar NAC, NACET, ACS48)
were administered twice a day for 4 days. The times of analysis for the iv treatment are: 20 , 100, 300, 600 , 1200, 2400. At the indicated times, the levels of H2S were
measured in the plasma through colorimetric HPLC. Data are the mean±SD; n¼ 3. p< .001 vs vehicle.
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are further metabolised and excreted after the removal of glycine
and glutamic acid and the acetylation of the cysteinyl amino
group to form mercapturic acid33.
A decrease in GSH has been linked to the onset and/or pro-
gression of many diseases, and there is consequently considerable
interest in counteracting this phenomenon. N-acetylcysteine has
been widely studied as a GSH enhancer, as it is considered to be
a source of Cys. However, despite the fact that it has been tested
for treating numerous diseases, up until now it has only been
used for paracetamol intoxication, since, in most cases, it did not
work to ameliorate the symptoms12. Other compounds have
therefore been studied as an alternative to NAC8,34.
Figure 7. Protection against acetaminophen toxicity. Three out of four groups of rats were treated ip with 2 g/kg acetaminophen (APAP). 150 before acetaminophen
treatment and 2 h and 4 h after, 50mg/kg ACS94 (or equimolar NAC) or vehicle was orally administered to rats. Vehicle group: rats treated with salineþDMSO and
carboxymethylcellulose. The glutathione (GSH), protein thiols (PSH), and homocysteine (Hcys) were then measured in the organ homogenates through HPLC. The total
Hcys was measured in the plasma. The GSH and PSH levels are reported for the liver, kidneys, and heart, whereas the homocysteine levels are reported for the liver,
kidneys, and lungs. Data are the mean± SD; n¼ 4 for each group p< .05 vs APAPþ vehicle; p< .01 vs APAPþ vehicle; §p< .05 vs APAPþNAC; §§p< .01
vs APAPþNAC.
Table 2. Study of the protective effect of NAC and ACS94 on several damage biomarkers induced by paracetamol overdose in rats.
Sample Urea (mg/dl) Creatinine (mg/dl) GOT/AST (U/L) GPT/ALT (U/L) LDH (U/L) Uric acid (mg/dl)
Control 41.2 ± 2.0 0.37 ± 0.01 60.2 ± 9.23 62.2 ± 6.8 520 ± 12 0.30 ± 0.01
Paracetamol 43.1 ± 2.1 0.53 ± 0.02## 584 ± 11## 82.1 ± 3.35# 3229 ± 51## 0.66 ± 0.08##
ParacetamolþNAC 32.2 ± 3.2 0.43 ± 0.58 560 ± 20 78.0 ± 14.2 3003 ± 210 0.51 ± 0.02
ParacetamolþACS94 32.2 ± 4.7 0.32 ± 0.02,§§ 322 ± 19,§§ 70.7 ± 6.4,§ 2006 ± 158,§§ 0.41 ± 0.05,§§
Data are the mean ± SD. n¼ 4 for each group.
p< .05 vs paracetamol;

p< .01 vs paracetamol; §p< .05 vs NAC; §§p< .01 vs NAC; #p< .05 vs control; ##p< .01 vs control.
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Although H2S biology is quite complex, interest in it is grow-
ing. In fact, even if H2S is known to be toxic for humans by target-
ing cytochrome-c oxidase, there is much evidence regarding its
protective role in several disease states, with these different
effects being related to its levels. At low physiological concentra-
tions, H2S can act as a modulator of numerous biochemical path-
ways, thus providing beneficial effects. Evidence of this is
available for the nervous, gastrointestinal, cardiovascular, and
respiratory systems35. Many studies have also been carried out
with the aim of selecting compounds that can deliver H2S to tar-
get tissues. These essentially fall into three categories: sulphide
salts, naturally occurring compounds, and synthetic H2S donors
5.
Although all of these seem to be promising, none of them have
yet been accepted for targeted therapeutic applications.
Therefore, research on this topic is ongoing.
We have recently studied two different synthetic compounds
that provided promising results in experiments with rats. One of
these is NACET, the ethyl ester of NAC. Chronic treatments with
NACET in comparison with equimolar NAC indicated that only
NACET was capable of increasing GSH significantly in most of
the analysed organs. Furthermore, only NACET was able to cross
the blood brain barrier, thus increasing the GSH in the brain. We
found that the pharmacokinetic profile of this molecule is peculiar,
in that it is readily absorbed and its bioavailability is quite high
(more than 60%), whereas the bioavailability of NAC is below 5%.
NACET was also able to increase the physiological levels of H2S
in plasma13. Other Cys analogues have been shown to possess
the ability to provide additional levels of H2S, such as S-propylcys-
teine, S-allylcysteine, S-propargylcysteine36. However, this property
is not common to all Cys derivatives, since, under our experimen-
tal conditions, H2S levels did not increase in the NAC-
treated animals.
Dithiolethiones were also shown to be effective at increasing
GSH levels in several rat organs, including the brain, and H2S lev-
els in plasma15,22,25,37. However, it is unclear how dithiolethiones
are per se capable of increasing GSH levels. It has been hypothes-
ised that several of the antioxidant enzymes involved in GSH syn-
thesis/metabolism, such as c-glutamylcysteine synthase, GSH
transferase, and GSH reductase, may be altered by these drugs3,38.
Similarly, although the mechanism by which dithiolethiones
modulate H2S levels is still unknown, in our experiments we
were able to observe a biphasic increase in the same, which can
be explained by admitting the involvement of two differ-
ent pathways.
ACS94 was formally obtained by conjugating a dithiolethione
moiety (ACS48) with cysteine ethyl ester. As hypothesised, it main-
tained the ability to increase both GSH and H2S levels in rat
organs and plasma, respectively (Figures 4(A), 5(A), and 6). ACS94
was as efficient as NACET and ACS48 at increasing GSH levels in
rat organs: in fact, liver, kidneys, lung, and heart showed higher
GSH levels with respect to the vehicle-treated animals. However,
our data indicate that the concomitant release of Cys and a
dithiolethione moiety does not increase GSH levels in a synergic
way. This can be explained by the fact that c-glutamylcysteine
synthetase (GCL, that catalyses the first step of GSH synthesis) is
regulated by non-allosteric feedback competitive inhibition (with
glutamate) through GSH39. However, ACS94 was found to be the
best H2S-releasing molecule in terms of both long lasting effect
and H2S plasma levels reached (Figure 6(B)). The dithiolethione
moiety seems to be responsible for this effect, as ACS48 and
ACS94 behaved similarly, whereas the increase induced by NACET
was less durable.
The metabolism of ACS94 is quite complex, as the molecule
can undergo: de-esterification reactions, hydrolysis reactions, and
thiol oxidation to disulphide by thiol-disulphide exchange reac-
tions. As a consequence of this, many metabolites can form
(Figures 2 and 3). The thiol-disulphide exchange reactions render
the metabolism of ACS94 particularly complex, as these are revers-
ible reactions and can involve many different thiol/disulphides
physiologically present in biological fluids. It should be also noted
that the disulphide metabolites of ACS94 can be distributed and
metabolised in a different way with respect to the reduced metab-
olites. For example, a fraction of the disulphides can covalently
bind to the Cys 34 of albumin, a rather peculiar kind of interaction
for a drug, which makes its metabolism even more complex. As a
matter of fact, the equilibrium between the bound fraction and
the free drug is governed by the presence of low molecular mass
thiols (LMM-SH) according to the reaction (1), and the concentra-
tion of these molecules changes greatly under several physio-
pathological conditions, even depending on the different vascular
districts24,40:
PSHþ LMMSS$ PSSLMMþ LMMSH: (1)
However, after 60min from the treatment with ACS94, we
could observe a higher concentration of its de-esterified forms
within cells of all the studied rat tissues with respect to the
plasma. It is probable that, in analogy to NACET, the fraction of
ACS94 that is de-esterified is trapped within cells, as it becomes
more hydrophilic, and, consequently, its exit is restricted. Within
the cells, it is then hydrolysed mainly to cysteine and the dithiole-
thione moiety. Both cysteine and ACS48 are efficient GSH
enhancers (Figure 4). The presence of the ethyl ester group in the
molecule, increasing its lipophilicity, likely favours the membrane
crossing and trapping of ACS94 (after de-esterification) within
cells, similarly to NACET. However, unlike NACET, the occurrence
of the dithiolethione moiety allows for both a rapid increase and
a longer maintenance of H2S production.
The evidence that ACS94 also maintained the ability to lower
Hcys in plasma (and in some rat organs, namely liver, kidneys, and
lung) (Figures 4(B) and 5(B)) may be of pharmacological interest.
High levels of Hcys are suspected to contribute to the pathogen-
esis of cardiovascular diseases and other chronic conditions41–43.
Until recently, the pharmacological treatments for hyperhomocys-
teinaemia have primarily focused upon the supplementation of
folic acid and other B vitamins. However, while effective at
decreasing Hcys levels, these vitamins do not seem to be capable
of decreasing the incidence of cardiovascular events in
humans44,45. Meanwhile, alternative approaches to reducing Hcys
concentrations are being researched, and ACS94 may represent a
promising drug for this purpose. We had already reported that
other molecules containing dithiolethiones, such as ADTOH,
ACS14, and ADT, lower the concentration of Hcys36,37. We can
hypothesise that this Hcys-lowering effect may be related to the
concomitant increase in GSH and H2S. In fact, the decrease in
Hcys could result from the stimulation of the transsulphuration
pathway (TSP), which is known to be redox regulated46. By influ-
encing the thiol-disulphide balance, ACS94 can cause an enhance-
ment of TSP, which, in turn, may be responsible for the increased
Cys levels we measured in the rat organs (data not shown), as
well as the increased GSH levels. In fact, the observed increase of
H2S could be due to both enhanced TSP and increased Cys levels.
This might also explain the biphasic release of H2S from the
dithiolethiones: the initial increase (observed immediately after
the drug’s administration) is likely due to its direct release from
the dithiolethione-containing drugs, whereas the later increase
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(6–24 h after the treatments) may be attributable to the activation
of TSP and generation from Cys. Moreover, our previous data indi-
cate that dithiolethione treatments are followed by enhanced Cys
and GSH release from the intracellular compartment to the blood,
thus leading to an increase in the thiol to disulphide ratio in the
plasma. Considering that Hcys mainly occurs in plasma as a disul-
phide (both with proteins and with low molecular mass thiols),
the thiols occurring in the plasma can react with these disulphide
forms to release free Hcys, which, in turn, can be metabolised.
NACET was also able to decrease Hcys, and, like the Cys prodrug,
we can hypothesise that it may promote a decrease in Hcys levels
by reducing the disulphide forms of Hcys itself in the extracellular
milieu, but without any involvement of the TSP.
Another pharmacological effect that ACS94 may exert is that of
liver protection against intoxication with APAP. As a supplier of
GSH, NAC is regarded as the antidote of choice for treating acet-
aminophen overdose. However, under our experimental condi-
tions, NAC was only shown to exert some degree of protection
against kidney toxicity (see Table 2, data of creatinine and uric
acid), whereas ACS94 was more efficient at also protecting the
liver against APAP damage, probably by virtue of the dithiole-
thione moiety, as well as its better pharmacokinetics with respect
to NAC. In fact, only ACS94 was able to significantly increase the
levels of GSH and protein thiols (PSH) in both the liver and kid-
neys (Figure 7). These data are consistent with previous observa-
tions, which indicated both NACET and dithiolethiones as
hepatoprotective agents against APAP damage13,47.
One limit of this study stays on the lack of information about
the toxic potential of the tested compound. The only information
we have comes from the 4-day oral treatment (10mg/kg twice a
day). Along this time, we could not observe any change in the rat
weight for every kind of administered drug (ACS94, ACS48, NAC,
NACET). Further long-lasting experiments, with targeted experi-
ments and dose–response studies are necessary to characterise
the toxic potential of ACS94.
Conclusions
In this article we have proposed a new synthetic compound that
possesses several promising pharmacological properties: 1) it has
good pharmacokinetics, as it rapidly enters the cells; 2) it releases
H2S in vivo, and this effect is long-lasting; 3) it is capable of pro-
viding antioxidant protection by increasing GSH and by possess-
ing an –SH group itself; 4) it significantly decreases Hcys levels in
several rat target organs and in plasma; 5) it prevents APAP
induced thiol depletion in rat kidneys and liver. ACS94 can affect
the metabolic pathways relating to Hcys, Cys, GSH (by TSP path-
way), and H2S. The dysregulation of these pathways is associated
with several pathologies, mostly at a cardiovascular level45. By
decreasing Hcys and increasing H2S and GSH, ACS94 is potentially
capable of protect against these disorders. Moreover, thanks to its
antioxidant properties, it can have beneficial effects by protecting
the cells against ROS overproduction, which mostly occurs in
inflammatory diseases. Considering that acetaminophen poisoning
currently represents the most common cause of ALF in North
America and Europe48, the protection offered against APAP intoxi-
cation is another effect worth of further investigation.
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